FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1191-1194 October 19, 2000 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Wood, A. J.J.

To the Editor: Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and death from vascular causes) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. This indication is based on the results of a clinical trial, involving 19,185 patients, in which clopidogrel was compared with aspirin in patients at risk for ischemic events. The study's steering committee estimated that clopidogrel would prevent about 24 major clinical events for every 1000 patients treated for one year.¹

Clopidogrel was approved by the Food and Drug Administration (FDA) in November 1997 and . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bennett, C. L., Kim, B., Zakarija, A., Bandarenko, N., Pandey, D. K., Buffie, C. G., McKoy, J. M., Tevar, A. D., Cursio, J. F., Yarnold, P. R., Kwaan, H. C., De Masi, D., Sarode, R., Raife, T. J., Kiss, J. E., Raisch, D. W., Davidson, C., Sadler, J. E., Ortel, T. L., Zheng, X. L., Kato, S., Matsumoto, M., Uemura, M., Fujimura, Y. (2007). Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 50: 1138-1143 [Abstract] [Full Text]